Market Newsdesk

Cohu To Announce Second Quarter 2022 Results on July 28

POWAY, Calif.–(BUSINESS WIRE)–
Cohu, Inc. (NASDAQ: COHU), a global leader in back-end semiconductor equipment and services will release financial results for second quarter on Thursday, July 28, 2022 at 1:00 p.m. Pacific Time/4:00 p.m. Eastern Time.

The Company will host a live conference call and webcast with slides to discuss the results at 1:25 p.m. Pacific Time/4:25 p.m. Eastern Time.

Interested parties may listen live via webcast on Cohu’s investor relations website at https://cohu.gcs-web.com/news-events/event-calendar.

To participate via telephone and join the call live, please register in advance at https://register.vevent.com/register/BI0bf4c05ab99f4800b14c0560949325e1 to receive the dial-in number along with a unique PIN number that can be used to access the call.

The webcast replay will be available on the Company’s website through July 28, 2023 at www.cohu.com.

About Cohu:

Cohu (NASDAQ: COHU) is a global leader in back-end semiconductor equipment and services, delivering leading-edge solutions for the manufacturing of semiconductors. Additional information can be found at www.cohu.com.

For press releases and other information of interest to investors, please visit Cohu’s website at www.cohu.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005786/en/

Cohu, Inc.

Jeffrey D. Jones – Investor Relations

858-848-8106

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Semiconductor Hardware Manufacturing Other Manufacturing Technology

MEDIA:

Logo

ITHAX Acquisition Corp. and Mondee, Inc. Announce Completion of Business Combination

Mondee to begin trading on the Nasdaq on July 19, 2022 under ticker symbol MOND and MONDW

NEW YORK & SAN MATEO, Calif.–(BUSINESS WIRE)–
ITHAX Acquisition Corp. (“ITHAX”) (NASDAQ: ITHX), a publicly traded special purpose acquisition company, today announced the completion of its business combination with Mondee Holdings II, Inc., the high-growth, travel technology company and marketplace.

In connection with the completion of the business combination, ITHAX has been renamed Mondee Holdings, Inc. (“Mondee” or “the Company”) and its Class A common stock and warrants are expected to commence trading on the Nasdaq on July 19, 2022 under the ticker symbols “MOND” and “MONDW”, respectively.

“We are well-positioned to consolidate our EBITDA profitability and accelerate our growth strategy as a result of this business combination,” said Prasad Gundumogula, Founder and Chief Executive Officer of Mondee. “The capital raised through this transaction along with our new access to the public markets will allow Mondee to capitalize on the massive organic and inorganic growth opportunities in the travel industry and continue to advance our travel technology platforms and next-generation solutions.”

“We are truly delighted to complete our business combination with Mondee, a market leading company that we expect will continue to disrupt the travel market,” said Orestes Fintiklis, Chief Executive Officer and Chairman of ITHAX and Founder of Ithaca Capital. “Mondee has a proven track record of profitable growth and success, giving us confidence that the Company will continue to deliver long-term value to shareholders and we look forward to continuing to support them in the years ahead.”

About Mondee Holdings, Inc.:

Mondee Holdings, Inc. is a group of leading travel technology, service, and content companies driving disruptive innovative change in the leisure and corporate travel markets. They deliver a revolutionary technology platform of SaaS, mobile, and cloud products and services to a global customer base, processing over 50 million daily searches and multi-billion dollars of transactional volume yearly. Founded in 2011, Mondee is headquartered in Silicon Valley, California, with 17 offices in the USA and Canada, and operations in India, Thailand, and Ireland. On December 20, 2021, Mondee entered into a definitive business combination agreement with ITHAX Acquisition Corp. (Nasdaq: ITHX) which resulted in Mondee becoming a publicly listed company on Nasdaq under the ticker symbol “MOND”. For more information, please visit https://www.mondee.com.

Forward-Looking Statements:

Certain statements in this document may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included herein, regarding the business combination between ITHAX Acquisition Corp., an exempted company incorporated in the Cayman Islands with limited liability under company number 366718 (“ITHAX”) and Mondee Holdings II, Inc., a Delaware corporation (“Mondee”), the benefits of the transaction and the public company’s future financial performance following the transaction, as well as ITHAX’s and Mondee’s strategy, future operations, financial position, estimated revenues, and losses, projected costs, prospects, plans and objectives of management are forward looking statements. When used herein, including any oral statements made in connection herewith, the words “anticipates,” “approximately,” “believes,” “continues,” “could,” “estimates,” “expects,” “forecast,” “future, ” “intends,” “may,” “outlook,” “plans,” “potential,” “predicts,” “propose,” “should,” “seeks,” “will,” or the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Such forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by both ITHAX and its management, and Mondee and its management, as the case may be, are inherently uncertain. Except as otherwise required by applicable law, ITHAX disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date hereof. ITHAX cautions you that these forward-looking statements are subject to risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of ITHAX. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to meet Nasdaq’s listing standards; (2) costs related to listing on Nasdaq, (3) the ability to implement business plans, forecasts, and other expectations after the Business Combination, (4) the outcome of any legal proceedings that may be instituted against ITHAX, Mondee, the combined company or others and any definitive agreements with respect thereto; (5) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (6) costs related to the business combination; (7) changes in applicable laws or regulations, including legal or regulatory developments; (8) the possibility that ITHAX, Mondee or the combined company may be adversely affected by other economic, business, and/or competitive factors; (9) the impact of COVID-19 on the combined company’s business; (10) adverse changes in general market conditions for travel services, including the effects of macroeconomic conditions, terrorist attacks, natural disasters, health concerns, civil or political unrest or other events outside the control of the parties; (11) significant fluctuations in the combined company’s operating results and rates of growth; (12) dependency on the combined company’s relationships with travel agencies, travel management companies and other travel businesses and third parties; (13) payment-related risks; (14) the combined company’s failure to quickly identify and adapt to changing industry conditions, trends or technological developments; (15) unlawful or fraudulent activities in the combined company’s operations; (16) any significant IT systems-related failures, interruptions or security breaches or any undetected errors or design faults in IT systems of the combined company; (17) exchange rate fluctuations; and (18) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements and Risk Factor Summary” in ITHAX’s final prospectus relating to its initial public offering dated February 1, 2021 and in subsequent filings with the U.S. Securities and Exchange Commission (the “SEC”), including the registration statement on Form S-4 relating to the business combination that ITHAX filed with the SEC and declared effective by the SEC on June 27, 2022 and the definitive proxy statement/prospectus contained therein that was mailed to ITHAX’s shareholders on or about June 27, 2022. There may be additional risks that neither ITHAX nor Mondee presently know of or that ITHAX or Mondee currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.

Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Author and any of their affiliates, directors, officers and employees expressly disclaim any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement to reflect events or circumstances after the date on which such statement is being made, or to reflect the occurrence of unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005769/en/

Media:

For Mondee:

Media

[email protected]

Investor Relations

[email protected]

For ITHAX:

Investor Relations

[email protected]

KEYWORDS: United States North America California New York

INDUSTRY KEYWORDS: Finance Vacation Other Travel Professional Services Travel

MEDIA:

Logo

DermTech Appoints Two New Board Members

LA JOLLA, Calif.–(BUSINESS WIRE)–
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company’s board of directors, effective July 18,2022. These appointments expand DermTech’s board of directors to eight members.

“We are excited to welcome Kirk and Mark as new independent directors,” commented Matt Posard, DermTech’s chairman. “They are both accomplished life science executives, with an established track record in building companies, business development, capital formation and strategic partnerships. Their perspectives in guiding high-growth companies will provide our board with valuable insights as we look ahead to important operating milestones.”

Dr. Malloy has spent over 25 years in key leadership positions with Illumina, Inc., Biosite Inc. and QIAGEN Inc., and most recently served as the chief executive officer of Verogen, Inc., from August 2017 to August 2018 after founding the company and securing initial funding. Dr. Malloy is currently founder and principal at BioAdvisors, LLC, where he provides strategic consulting services to life science, diagnostics and genomics companies. Prior to founding BioAdvisors in April 2016, he was at Illumina, Inc. from 2002 to 2016, most recently as senior vice president and general manager of Life Sciences and Applied Markets from January 2014 to April 2016. From May 2005 to December 2013, he served as vice president of Global Customer Solutions; he was also vice president of Global Quality from December 2005 to May 2007. Dr. Malloy joined Illumina in 2002 as senior director of Global Customer Solutions. Before Illumina, he held various commercial leadership positions at Biosite Inc. and QIAGEN Inc. Dr. Malloy currently serves as a director for NanoString Technologies, Inc. (NASDAQ: NSTG), as chairman of the board for cancer diagnostics company, Tagomics, and is a director for several private genomics tools companies. Dr. Malloy earned his B.S. in Biology from the University of Miami, and his M.S. and Ph.D. from the University of Delaware and held post-doctoral and instructor positions at Boston University and Northeastern University.

“I am impressed with DermTech’s progress as it works to meaningfully improve the standard of care in dermatology with precision genomics,” said Dr. Malloy. “The Company is reshaping the dermatology landscape by bringing non-invasive solutions to patients that need better options. I am thrilled to join a passionate board of directors with a unified vision.”

Mr. Capone is an accomplished life sciences executive, most recently serving as president and chief executive officer of Myriad Genetics which he transformed from a pioneering start-up to one of the largest precision medicine companies in the world. During his 17-year tenure, Myriad Genetics developed and launched more than a dozen reimbursed molecular diagnostics achieving total annual revenues of more than $800 million. Prior to Myriad, he spent 17-years at Eli Lilly and Company in various leadership positions. Mr. Capone currently serves as chief executive officer of Precision Medicine Advisors, LLC, and is a non-executive board member of Abcam plc and Owlstone Medical. He received a B.S. in Chemical Engineering from Penn State University graduating with highest distinction, and his M.S. in Chemical Engineering (biotechnology emphasis) and Management from Massachusetts Institute of Technology.

“DermTech brings non-invasive precision dermatology solutions to patients that need better options,” stated Mr. Capone. “The Company’s robust product pipeline addresses large markets in skin disease including cancer. I am honored to join the board and support DermTech’s mission to improve the lives of millions with individualized care.”

About DermTech

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using its Smart Stickers™. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products and the market opportunity for these products, DermTech’s positioning and potential revenue growth, financial outlook and future financial performance, operating milestones, implications and interpretations of any study results, the evaluation and judgments of the skills and experiences of the new members of DermTech’s board, and expectations with respect to their future contributions to DermTech, and DermTech’s ability to expand its product offerings and develop pipeline products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005760/en/

Steve Kunszabo

DermTech

(858) 291-1647

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology General Health Health Genetics Oncology

MEDIA:

Posted on July 18, 2022 4:08 pm

Altice USA to Hold Conference Call to Discuss Q2 2022 Results

Altice USA to Hold Conference Call to Discuss Q2 2022 Results

NEW YORK–(BUSINESS WIRE)–
Altice USA (NYSE: ATUS) will host a conference call on Wednesday, August 3, 2022 at 4:30 p.m. EDT to discuss financial and operating results for the first quarter ended June 30, 2022. A press release reporting the results will be issued at 4:05 p.m. EDT.

The call will be led by Dexter Goei, CEO, and Michael Grau, CFO.

Dial-in Access Telephone Numbers:

Participant Dial-In: 877-404-9653 / +1 201-689-8856

A live webcast of the presentation will be available on the following website: here.

Click here for a company-compiled summary of the consensus estimates for Altice USA results.

The presentation for the conference call will be made available prior to the call on the company’s investor relations website: https://investors.alticeusa.com.

About Altice USA

Altice USA is one of the largest broadband communications and video services providers in the United States, delivering broadband, video, mobile, proprietary content, and advertising services to more than 5 million residential and business customers across 21 states through its Optimum and Suddenlink brands. The company operates a4, an advanced advertising and data business, which provides audience-based, multiscreen advertising solutions to local, regional, and national businesses and advertising clients. Altice USA also offers hyper-local, national, international, and business news through its News 12, Cheddar and i24NEWS networks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005651/en/

Investor Relations

Nick Brown: +1 (917) 589-9983 / [email protected]

Sarah Freedman: +1 (631) 660-8714 / [email protected]

Communications

Lisa Anselmo: +1 (516) 279-9461 / [email protected]

Janet Meahan : +1 (516) 519-2353 / [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Networks Audio/Video Mobile/Wireless Technology Telecommunications

MEDIA:

Posted on July 18, 2022 4:08 pm

Palantir Announces Date of Second Quarter 2022 Earnings Release and Webcast

Palantir Announces Date of Second Quarter 2022 Earnings Release and Webcast

DENVER–(BUSINESS WIRE)–
Palantir Technologies Inc. (NYSE: PLTR) announced today that results for its second quarter ended June 30, 2022 will be released on Monday, August 8, 2022, prior to the open of U.S. markets. Palantir will host a webcast to discuss its results at 6:00 AM MT / 8:00 AM ET.

A live webcast and replay will be available at investors.palantir.com, and participants can pre-register here. In addition, shareholders can submit and vote on questions by visiting https://app.saytechnologies.com/palantir-2022-q2.

About Palantir Technologies Inc.

Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005628/en/

Investor Relations

[email protected]

Media

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Software Technology Data Management

MEDIA:

Logo

Cvent To Announce Second Quarter 2022 Financial Results on August 4, 2022

TYSONS, Va.–(BUSINESS WIRE)–
Cvent (Nasdaq: CVT), a market-leading meetings, events, and hospitality technology provider, today announced that it will release its second quarter 2022 financial results on Thursday, August 4, 2022, after market close. On that day, management will hold a conference call and webcast at 5:00 p.m. ET to review and discuss its results.

To listen to the audio webcast of the live conference call, please visit https://events.q4inc.com/attendee/730463585. The live conference call can also be accessed by dialing the following:

1-888-440-5667 (Domestic)

1-646-960-0476 (International)

Conference ID: 7981326

A webcast replay of the call will be available at https://investors.cvent.com/ after the conclusion of the conference call.

A telephone replay of the conference call will also be available after the call until 11:59 p.m. ET on August 11, 2022, and can be accessed by dialing the following:

1-800-770-2030 (Domestic)

1-647-362-9199 (International)

Conference ID: 7981326

About Cvent

Cvent Holding Corp. (Nasdaq: CVT) is a leading meetings, events, and hospitality technology provider with more than 4,300 employees and nearly 21,000 customers worldwide. Founded in 1999, the company delivers a comprehensive event marketing and management platform and offers a global marketplace where event professionals collaborate with venues to create engaging, impactful experiences. Cvent is headquartered in Tysons, Virginia, just outside of Washington D.C., and has additional offices around the world to support its growing global customer base. The comprehensive Cvent event marketing and management platform offers software solutions to event organizers and marketers for online event registration, venue selection, event marketing and management, virtual and onsite solutions, and attendee engagement. Cvent’s suite of products automate and simplify the entire event management process and maximize the impact of in-person, virtual, and hybrid events. Hotels and venues use Cvent’s supplier and venue solutions to win more group and corporate travel business through Cvent’s sourcing platforms. Cvent solutions optimize the entire event management value chain and have enabled clients around the world to manage millions of meetings and events. For more information, please visit Cvent.com, or connect with us on Facebook, Twitter or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005655/en/

Investor Relations

[email protected]

Media Relations

Erica Stoltenberg

[email protected]

(571) 378-6240

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Other Entertainment General Entertainment Entertainment Events/Concerts

MEDIA:

Logo

Vertex to Announce Second Quarter 2022 Financial Results on August 4

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2022 financial results on Thursday, August 4, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1 (412) 902-6510 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2022 Earnings Call”.

The conference call will be webcast live and a link to the webcast can be accessed through Vertex’s website at www.vrtx.com in the “Investors” section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company’s website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Founded in 1989 in Cambridge, Mass., Vertex’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including 12 consecutive years on Science magazine’s Top Employers list and one of the 2021 Seramount (formerly Working Mother Media) 100 Best Companies. For company updates and to learn more about Vertex’s history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)

Source: Vertex Pharmaceuticals Incorporated

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005627/en/

Vertex Pharmaceuticals Incorporated Investors:

Manisha Pai, 617-961-1899

Miroslava Minkova, 617-341-6135

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health General Health Research Pharmaceutical Science Biotechnology

MEDIA:

Logo

Velo3D to Announce Second-Quarter 2022 Results on August 9, 2022

CAMPBELL, Calif.–(BUSINESS WIRE)–Velo3D, Inc. (NYSE: VLD) — a leading additive manufacturing technology company for mission-critical metal parts, announced today that it will release its second quarter 2022 financial results after the market close on Tuesday, August 9, 2022.

The company will host an earnings conference call and webcast to discuss its financial results at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time the same day. The U.S. dial-in for the call is (877) 704-2771 and (201) 689-8732 for non-U.S. callers. Please ask to be joined to the Velo3D call.

The live webcast of the call can be accessed from the Events page of the Investor Relations section of Velo3D’s website at ir.velo3d.com, along with the company’s earnings press release and presentation which will be posted prior to the start of the conference call.

About Velo3D:

Velo3D is a metal 3D printing technology company. 3D printing—also known as additive manufacturing (AM)—has a unique ability to improve the way high-value metal parts are built. However, legacy metal AM has been greatly limited in its capabilities since its invention almost 30 years ago. This has prevented the technology from being used to create the most valuable and impactful parts, restricting its use to specific niches where the limitations were acceptable.

Velo3D has overcome these limitations so engineers can design and print the parts they want. The company’s solution unlocks a wide breadth of design freedom and enables customers in space exploration, aviation, power generation, energy and semiconductor to innovate the future in their respective industries. Using Velo3D, these customers can now build mission-critical metal parts that were previously impossible to manufacture. The end-to-end solution includes the Flow™ print preparation software, the Sapphire^® family of printers, and the Assure™ quality control system—all of which are powered by Velo3D’s Intelligent Fusion™ manufacturing process. The company delivered its first Sapphire^® system in 2018 and has been a strategic partner to innovators such as SpaceX, Honeywell, Honda, Chromalloy, and Lam Research. Velo3D has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2021. For more information, please visit https://www.velo3d.com, or follow the company on LinkedIn or Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005160/en/

Investor Relations:

Velo3D

Bob Okunski, VP Investor Relations

[email protected]

Media Contacts:

Velo3D

Dan Sorensen, Senior Director of PR

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Machine Tools, Metalworking & Metallurgy Technology Manufacturing Software Other Manufacturing Machinery

MEDIA:

Logo